Q3 2026
Nov 7, 2026
Aflac’s third-quarter results were mixed, and the stock rose 0.8% after earnings—roughly flat. U.S. sales and premiums grew, while Japan sales declined against a difficult comparison; the available transcript excerpt provides no further financial detail to assess the quarter’s earnings trajectory.
Key takeaways
- Aflac reported net earnings per diluted share of $0.61 and adjusted earnings per diluted share of $2.43; the CFO later cited adjusted EPS of $2.46 excluding foreign-currency effects.
- Aflac Japan sales fell 4% year over year to ¥18.8 billion, but were up 3% for the first nine months. Management attributed the quarterly decline to a challenging comparison following the prior-year Miraito Cancer Insurance launch.
- Aflac US sales increased 3.5% and net earned premiums rose 3.3% year over year; premium persistency was 79.7%.
- Aflac US reported a 27.7% pretax profit margin. Japan premium persistency was 92.9%.
- Aflac returned $1.1 billion to shareholders through dividends and share repurchases in the quarter, and $3.7 billion in the first nine months.
Q2 2026
Aug 9, 2026
Aflac’s shares fell 1.6% post-earnings as investors digested a deceleration in Japan sales against a strong prior-year quarter and margin pressures indicated by variable investment income falling short of expectations. The mixed results and cautious tone on growth moderated enthusiasm.
Key takeaways
- Japan sales declined 5.6% year-over-year in Q2 due to a tough comparison from the Miraito cancer insurance launch in 2025, though H1 sales remained up 7%.
- Aflac U.S. posted a 2.6% increase in year-over-year sales, supported by growth in group voluntary products and dental & vision lines.
- Variable investment income was $72 million below long-term return expectations, pressuring underlying margins and offsetting some operational gains.
- Japan’s benefit ratio improved by 250 basis points to 64%, reflecting lower benefit payouts but overall net earned premiums declined 3.7%.
- Capital return remained strong with $1.3 billion distributed to shareholders in Q2 through dividends and buybacks, supporting steady capital deployment despite mixed operational signals.
Q1 2026
May 1, 2026
Shares of Aflac closed down 2.9% following Q1 2026 results, as the market appeared unenthused despite robust reported sales gains in Japan and the U.S. The absence of positive surprise in margins, outlook, or guidance likely left investors looking for more than incremental operating momentum.
Key takeaways
- Adjusted earnings per share rose 6.6% year-over-year to $1.77 (ex-FX), aided by reserve remeasurement gains but modestly offset by softer variable investment income.
- Japan segment delivered a notable 25.5% increase in sales, propelled by new medical and cancer insurance products.
- U.S. operations saw sales increase 2.9% year-over-year, with net earned premium up 3.5% and stable premium persistency at 79.3%.
- Capital returns remained robust with $1.3 billion returned to shareholders via buybacks and dividends in the quarter.
- Margins and guidance commentary remained steady, with no clear indicators of meaningful upward revisions or acceleration that might have driven a more positive market response.
Q3 2025
Nov 7, 2025
Aflac Incorporated reported solid third-quarter 2025 results, with adjusted earnings per diluted share rising 15.3% year-over-year to $2.49, driven by strong sales performance in both Japan and the U.S.
Key takeaways
- Aflac Japan recorded an impressive 11.8% year-over-year sales increase, notably fueled by a 42% surge in cancer insurance sales.
- New sales in Aflac U.S. reached $390 million, marking a 2.8% increase from the previous year, maintaining a strong premium persistency of 79%.
- Aflac repurchased a record $1 billion in shares and paid $309 million in dividends during the quarter, reinforcing its commitment to shareholder returns.
- The company celebrated 43 consecutive years of dividend increases, highlighting its strong financial position and capital management strategy.
- Continued emphasis on underwriting discipline and premium persistency is expected to drive further net earned premium growth, supporting the company’s long-term objectives.